Context Therapeutics (NASDAQ:CNTX) Shares Up 8.7% – Should You Buy?

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) were up 8.7% during trading on Monday . The company traded as high as $1.16 and last traded at $1.13. Approximately 1,536,834 shares traded hands during mid-day trading, an increase of 216% from the average daily volume of 486,535 shares. The stock had previously closed at $1.04.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Context Therapeutics to a “sell” rating in a report on Saturday, November 22nd. HC Wainwright upped their price objective on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim began coverage on shares of Context Therapeutics in a research report on Thursday, September 18th. They set a “buy” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.40.

Context Therapeutics Stock Performance

The stock has a fifty day simple moving average of $1.17 and a two-hundred day simple moving average of $0.91. The stock has a market cap of $103.82 million, a price-to-earnings ratio of -4.71 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Equities analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors have recently made changes to their positions in CNTX. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics during the 3rd quarter valued at about $100,000. Vanguard Group Inc. lifted its stake in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares during the period. Finally, Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the period. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.